2017 was a record year for class action securities litigation, and life sciences companies continued to be popular targets of such lawsuits. During 2017, plaintiffs filed a total of 88 class action securities lawsuits against life sciences companies, a more than 30% increase from the previous year, and a more than 225% increase from only five years prior.
In the most recent edition of our annual survey, Dechert litigators David H. Kistenbroker, Joni S. Jacobsen and Angela M. Liu examine these trends as well why life sciences companies have remained attractive targets for class action securities fraud claims. They also offer best practices for life sciences companies to reduce their risk of being targeted.
Please see full Survey below for more information.